NCT01550224View on ClinicalTrials.gov

Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 1, 2013

Primary Completion Date

November 17, 2014

Study Completion Date

November 17, 2014

Conditions
Acute Myeloid Leukemia With 11q23-abnormality in Relapse
Interventions
DRUG

Temozolomide

An alkylating agent administered for induction per standard of care at 200 mg/m²/day for 7days.

DRUG

Vorinostat

A synthetic hydroxamic acid derivative with antineoplastic activity administered for both groups at 500 mg orally 3 times daily for 3 days prior to Temozolomide 200 mg/m²/day.

Trial Locations (1)

94305

Stanford University Medical Center, Stanford

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Steven E. Coutre

OTHER

NCT01550224 - Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter